Whitney Rhodes

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.

Vincent Chung, Mark D. Kochenderfer, Nagendra Natarajan, Grant R. Williams et autres

us, gb (code pays fourni par la source)

Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3.

A. Patel, Ashley Ann Laursen, Paul Cockrum, Yutong Liu et autres

us, gb (code pays fourni par la source)

Table A1: ICD-9-CM Neoplasm Terms for Lung Cancer from Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

R. Donald Harvey, Suanna S. Bruinooge, Li Chen, Elizabeth Garrett‐Mayer et autres

Data from Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

R. Donald Harvey, Suanna S. Bruinooge, Li Chen, Elizabeth Garrett‐Mayer et autres

Data from Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

R. Donald Harvey, Suanna S. Bruinooge, Li Chen, Elizabeth Garrett‐Mayer et autres

Table A1: ICD-9-CM Neoplasm Terms for Lung Cancer from Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

R. Donald Harvey, Suanna S. Bruinooge, Li Chen, Elizabeth Garrett‐Mayer et autres

Abstract 4118: Brain metastases (BM) and next-generation sequencing (NGS) timing: Real-world (RW) outcomes for patients (pts) with advanced non-small cell lung cancer (aNSCLC) and MET exon 14 skipping mutations (METex14)

Xiuning Le, Stephen Robb, Nydia Caro, Simona Doria et autres

us, ch (code pays fourni par la source)

Utilization of External Control Arm to Contextualize Clinical Efficacy of Tisagenlecleucel Treated Among Patients with Relapsed/Refractory Follicular Lymphoma from the Single-Arm Elara Trial

Yanni Hao, Wei‐Chun Hsu, Craig S. Parzynski, Chiara Lobetti Bodoni et autres

us, ch (code pays fourni par la source)

Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer

Whitney Rhodes, Richard W DeClue, Neil A. Accortt, Ran Jin et autres

us (code pays fourni par la source)

1259P Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)

Xiuning Le, Jorge Martinalbo, Ariadna Holynskyj, Whitney Rhodes et autres

us, ch (code pays fourni par la source)

1260P Clinical outcomes of patients with BRAFv⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice

Barbara Melosky, Stefanie Knoll, I.S. Souef, Wei‐Hsin Wu et autres

ca, us, ch (code pays fourni par la source)

Healthcare Resource Utilization and Cost Among Patients Treated for Early-Stage Triple-Negative Breast Cancer

Amin Haiderali, Whitney Rhodes, Santosh Gautam, Min Huang et autres

us (code pays fourni par la source)